LiquidSeq Colorectal Cancer Panel (71 Genes)

What is Liquidseq colorectal cancer panel test?

Liquidseq colorectal cancer panel is a liquid biopsy test that analyzes circulating tumor DNA (ctDNA) from a blood sample to detect mutations across 71 genes relevant to colorectal cancer. This test uses Next Generation Sequencing (NGS) technology to identify genetic alterations in tumor DNA fragments shed into the bloodstream. The panel covers a broad range of genes involved in colorectal cancer pathogenesis, including KRAS, NRAS, BRAF, and others. This panel enables non-invasive, real-time molecular profiling without the need for a tissue biopsy.

Why consider Liquidseq colorectal cancer panel test?

• To monitor tumor genetics dynamically during treatment or disease progression.

• Useful when tumor tissue biopsy is unavailable, insufficient, or risky.

• Helps detect emerging resistance mutations or new actionable targets.

• Supports personalized treatment planning and therapy adjustments.

• Offers a minimally invasive option for ongoing surveillance.

Who should get tested for Liquidseq colorectal cancer panel test in Nagercoil?

• Patients with colorectal cancer, especially advanced or metastatic disease.

• Individuals unable to undergo tissue biopsy or with limited tumor tissue available.

• Patients requiring treatment monitoring or evaluation of resistance mutations during therapy.

• Oncologists seeking comprehensive, real-time tumor profiling via liquid biopsy.

It usually begins as benign growths called polyps which can become cancerous over time. CRC is one of the most common cancers worldwide. Early detection improves survival significantly. Diagnosis involve Colonoscopy, Fecal occult blood test (FOBT) or fecal immunochemical test (FIT), CT scans, MRI for staging and Molecular tests (e.g., COLORECTAL CANCER PROFILER NEXT) to detect mutations for personalized therapy